3 results
Primary: To characterize the safety and tolerability of PDR001 in combination with LCL161, everolimus, HDM201, QBM076 or panobinostat and to identify recommended doses and schedules for future studies.Secondary: To characterize changes in the immune…
The aim of this study is the efficacy of a simplified triple regimen at an energy setting of 12 J/cm2 instead of 2x2x15 J/cm2, without a cleaning phase in between, and its effect on the rate of stenosis and overall complications when using the Barrx…
The first objective is to evaluate the superiority of CHF 5259 pMDI (glycopyrrolate bromide) (50 µg total daily dose) versus placebo in terms of FEV1 AUC0-12h normalised by time on Day 42.Key Secondary objectiveTo evaluate the superiority of CHF…